**Master data summary table in the application of BRAT framework in the Wave 1 Case Study Report Natalizumab**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| GROUP | CATEGORY | OUTCOME | MEASURE | DRUG | COMMON PLACEBO | RELATIVE VALUE | OUTCOME ON VALUE SCALE |
|   |   |   |   |   | DRUG | EST | DESCRIPTION | EST | EST |
| Benefit | Relapse | Relapse | 2 year relapse rate | Placebo | Natalizumab PBO | 0.731 | rate ratio | 1 | 1.46 |
|   |   |   |  | Natalizumab |  | 0.73 |  | 0.32 | 0.47 |
|   |   |   |  | Beta-interferon |  | 0.73 |  | 0.82 | 1.19 |
|   |   |   |   | Glatiramer acetate |   | 0.73 |   | 0.71 | 1.04 |
|   | Disability progression | Disability progression | 6-month confirmed % progressing after 2 years | Placebo | Natalizumab PBO | 0.17 | hazard ratio | 1.00 | 0.23 |
|   |   |   | 6-month confirmed % progressing after 2 years | Natalizumab |  | 0.17 |  | 0.46 | 0.11 |
|   |   |   | 6-month confirmed % progressing after 2 years | Beta-interferon |  | 0.17 |  | 0.58 | 0.14 |
|   |   |   | 6-month confirmed % progressing after 2 years | Glatiramer acetate |   | 0.17 |   | 0.77 | 0.18 |
|   | Convenience | Convenience | Route and frequency of adminsitration | Placebo |  |   |  |  | oral od |
|   |   |   |  | Natalizumab |  |   |  |  | iv qm hosp |
|   |   |   |  | Beta-interferon |  |   |  |  | im qw |
|   |   |   |   | Glatiramer acetate |   |   |   |   | sc od |
| Risk | Infection | Reactivation of serious herpes viral infections |  | Placebo | Natalizumab PBO | 0% | event ratio | 1 | 0.0% |
|   |   |   |  | Natalizumab |  | 0% |  | 1.00 | 0.0% |
|   |   |   |  | Beta-interferon |  | 0% |  | 1.00 | 0.0% |
|   |   |   |   | Glatiramer acetate |   | 0% |  | 1.00 | 0.0% |
|   |   | PML |  | Placebo |  |  |  |  | 0.0% |
|   |   |   |  | Natalizumab |  |  |  |  | 0.151% |
|   |   |   |  | Beta-interferon |  |  |  |  | 0.000% |
|   |   |   |   | Glatiramer acetate |   |  |  |  | 0.000% |
|   | Reproduction toxicity | Congenital abnormalities |  | Placebo |  |  |  |  | 0.0% |
|   |   |   |  | Natalizumab |  |  |  |  | 0.0% |
|   |   |   |  | Beta-interferon |  |  |  |  | 0.0% |
|   |   |   |   | Glatiramer acetate |   |  |  |  | 0.0% |
|   | Liver Toxicity | Transaminases elevation  | ALT >5x ULN | Placebo | Natalizumab PBO | 4% | event ratio | 1 | 4.0% |
|   |   |   |  | Natalizumab |  | 4% |  | 1.25 | 5.0% |
|   |   |   |  | Beta-interferon |  | 4% |  | 1.00 | 4.0% |
|   |   |   |   | Glatiramer acetate |   | 4% |  | 1.00 | 4.0% |
|   | Neurological | Seizures |  | Placebo |  |  |  |  | 0% |
|   |   |   |  | Natalizumab |  |  |  |  | 0% |
|   |   |   |  | Beta-interferon |  |  |  |  | 3.0% |
|   |   |   |   | Glatiramer acetate |   |  |  |  | 0.0% |
|   | Others | Infusion reactions/injection reactions |  | Placebo | Natalizumab PBO | 18% | event ratio | 1 | 0.0% |
|   |   |   |  | Natalizumab |  | 18% |  | 1.34 | 23.6% |
|   |   |   |  | Beta-interferon |  | 18% |  | 1.00 | 17.6% |
|   |   |   |   | Glatiramer acetate |   | 18% |  | 1.53 | 26.9% |
|   |   | Hypersensitivity Reactions |  | Placebo | Natalizumab PBO | 0% | event ratio | 1.00 | 0.0% |
|   |   |   |  | Natalizumab |  | 0% |  | 0.00 | 0.0% |
|   |   |   |  | Beta-interferon |  | 0% |  | 1.00 | 0.0% |
|   |   |   |   | Glatiramer acetate |   | 0% |  | 1.50 | 0.0% |
|   |   | Flu-like reactions |  | Placebo | Beta-interferon PBO | 40% | event ratio | 1.00 | 39.9% |
|   |   |   |  | Natalizumab |  | 40% |  | 1 | 39.9% |
|   |   |   |  | Beta-interferon |  | 40% |  | 1.52 | 60.8% |
|   |   |   |   | Glatiramer acetate |   | 40% |  | 1 | 39.9% |

1) One year rate. Value tree outcome is the two year rate so this is doubled